Methods for Automated Anti-Neutrophil Cytoplasmic Antibodies Compared
By LabMedica International staff writers Posted on 21 Oct 2020 |
Image: The EUROPattern Microscope Live: Ultrafast fluorescence microscopy that automatically detects anti-neutrophil cytoplasmic antibodies (Photo courtesy of EUROIMMUN AG).
The detection of anti-neutrophil cytoplasmic antibodies (ANCA) by indirect immunofluorescence assays (IFA) is of diagnostic importance in vasculitis and some other inflammatory diseases.
Several laboratories use formaldehyde-fixed neutrophil granulocytes as an auxiliary substrate in addition to conventional ethanol fixation which is reported to be useful in differentiating between antinuclear antibody and ANCA and improves interpretation of patterns. Many, especially high throughput laboratories consider indirect immunofluorescence (IIF) methods cumbersome, labor intensive and time consuming.
A team of clinical scientists at the University of Debrecen (Debrecen, Hungary) collected serum samples from 570 individuals, whose referrals were suspicion of or follow-up for acute and chronic renal failure, ulcerative colitis, Crohn’s disease, systemic autoimmune diseases, vasculitis and autoimmune liver disorders. Five patients provided two samples.
Indirect immunofluorescence testing was performed using a reagent kit designed to be used with EUROPattern (EPa), EUROIMMUN’s computer-aided immunofluorescence microscope (Granulocyte Mosaic 13; EUROIMMUN AG, Lübeck, Germany). One reaction area on the microscope slide contains three biochips (2 x 2 mm, substrate coated cover slips), covered by ethanol- or formaldehyde-fixed human neutrophil granulocytes or granulocytes scattered on a HEp-2 cell layer, respectively. Fluorescein isothiocyanate labeled goat anti-human IgG was used as secondary antibody (conjugate), which was supplemented with Evans blue dye for red counterstaining of the cells.
Slides were processed manually and screening dilution of serum samples was 1:10. The automatic results and the digital images were presented to the user on a calibrated computer screen, who checked and validated the patterns. Finally, the slides were evaluated by means of traditional visual reading under an epifluorescence microscope (EUROStar II Plus, EUROIMMUN AG).
The team reported that agreement of discrimination between negative and non-negative samples was 86.1% comparing EPa and conventional reading, and it increased to 96.7% after on-screen user validation. Importantly, from the 334 samples classified as negative by EPa, 328 (98.2%) were also negative by conventional evaluation. Pattern recognition showed ‘moderate’ agreement between classical microscopic and EPa analysis and ‘very good’ agreement after user validation. Misclassification by EPa was dominantly due to the presence of anti-nuclear/cytoplasmic antibodies (incorrect pattern, 80/568) and the lower fluorescence cut-off of the automated microscope (false positives, 73/568).
The authors concluded that automated ANCA testing by EPa is a reliable alternative of classical microscopic evaluation, though classification of sera needs correction by trained personnel during on-screen validation. The study was published on September 28, 2020 in the journal Clinica Chimica Acta.
Several laboratories use formaldehyde-fixed neutrophil granulocytes as an auxiliary substrate in addition to conventional ethanol fixation which is reported to be useful in differentiating between antinuclear antibody and ANCA and improves interpretation of patterns. Many, especially high throughput laboratories consider indirect immunofluorescence (IIF) methods cumbersome, labor intensive and time consuming.
A team of clinical scientists at the University of Debrecen (Debrecen, Hungary) collected serum samples from 570 individuals, whose referrals were suspicion of or follow-up for acute and chronic renal failure, ulcerative colitis, Crohn’s disease, systemic autoimmune diseases, vasculitis and autoimmune liver disorders. Five patients provided two samples.
Indirect immunofluorescence testing was performed using a reagent kit designed to be used with EUROPattern (EPa), EUROIMMUN’s computer-aided immunofluorescence microscope (Granulocyte Mosaic 13; EUROIMMUN AG, Lübeck, Germany). One reaction area on the microscope slide contains three biochips (2 x 2 mm, substrate coated cover slips), covered by ethanol- or formaldehyde-fixed human neutrophil granulocytes or granulocytes scattered on a HEp-2 cell layer, respectively. Fluorescein isothiocyanate labeled goat anti-human IgG was used as secondary antibody (conjugate), which was supplemented with Evans blue dye for red counterstaining of the cells.
Slides were processed manually and screening dilution of serum samples was 1:10. The automatic results and the digital images were presented to the user on a calibrated computer screen, who checked and validated the patterns. Finally, the slides were evaluated by means of traditional visual reading under an epifluorescence microscope (EUROStar II Plus, EUROIMMUN AG).
The team reported that agreement of discrimination between negative and non-negative samples was 86.1% comparing EPa and conventional reading, and it increased to 96.7% after on-screen user validation. Importantly, from the 334 samples classified as negative by EPa, 328 (98.2%) were also negative by conventional evaluation. Pattern recognition showed ‘moderate’ agreement between classical microscopic and EPa analysis and ‘very good’ agreement after user validation. Misclassification by EPa was dominantly due to the presence of anti-nuclear/cytoplasmic antibodies (incorrect pattern, 80/568) and the lower fluorescence cut-off of the automated microscope (false positives, 73/568).
The authors concluded that automated ANCA testing by EPa is a reliable alternative of classical microscopic evaluation, though classification of sera needs correction by trained personnel during on-screen validation. The study was published on September 28, 2020 in the journal Clinica Chimica Acta.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms